Entera Bio (ENTX) EBIT Margin (2019 - 2025)

Entera Bio's (ENTX) quarterly EBIT Margin came in at 6102.38% in Q1 2025, down 114.12% on a QoQ basis from 2850.0% in Q4 2024.

Entera Bio (ENTX) EBIT Margin (2019 - 2025) Analysis & Trends

Entera Bio (ENTX) has 6 years of EBIT Margin data on file, last reported at 6102.38% in Q1 2025.

Quarterly EBIT Margin changed N/A year-over-year to 6102.38% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 27600.0% (down 2228508.0% YoY) and the FY2025 annual result came in at 27450.0%, down 2215442.0% from the prior year.
EBIT Margin declined to 6102.38% in Q1 2025, from 2850.0% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 1489.81% in Q1 2021 to a low of 35812.5% in Q3 2022.
A 4-year average of 8281.72% and a median of 4749.68% in 2022 frame the typical range for EBIT Margin.
Annual changes were most pronounced in 2021 — EBIT Margin surged 442489 bps — and 2022, when it tumbled 3351250 bps.
Tracing ENTX's EBIT Margin over 4 years: stood at 2477.58% in 2021, then sank by 785 bps to 21914.29% in 2022, then jumped by 87 bps to 2850.0% in 2024, then slumped by 114 bps to 6102.38% in 2025.
The last three EBIT Margin figures came in at 6102.38% (Q1 2025), 2850.0% (Q4 2024), and 7192.86% (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.15%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	32.54%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-35.57%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.75%
10	Entera Bio	161.44 Mn	150.13 Mn	-	-

Download Data